MG
TGTX icon

Michael Gelband’s TG Therapeutics TGTX Stock Holding History

Michael Gelband’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300,000
Closed -$4.57M – 1980
2024
Q1 		$4.57M Buy
+300,000
New +$4.78M 0.03% 419

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Michael Gelband's TGTX Position: Q2 2026 in Review

Michael Gelband opened a new position in TG Therapeutics (TGTX) in Q2 2026: 164,513 shares worth $9.04M. The stake represents 0.06% of the portfolio and ranks #321 among its holdings. This is a return to the name: Michael Gelband previously reported a position in TGTX as recently as Q4 2025.

Michael Gelband first reported a position in TGTX in Q2 2019 and has held it in 15 quarters since. The position peaked at $19.6M in Q2 2024. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Michael Gelband held 164,513 shares of TG Therapeutics worth $9.04M as of Q2 2026.
  • TG Therapeutics was a new Michael Gelband position in Q2 2026.
  • TG Therapeutics made up 0.06% of Michael Gelband's portfolio in Q2 2026, its #321 holding.
  • Michael Gelband first reported a position in TG Therapeutics in Q2 2019 and has held it in 15 quarters since.
  • Michael Gelband's TG Therapeutics position peaked at $19.6M in Q2 2024.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.